Molecular Biomarkers of Vascular Dysfunction in Obstructive Sleep Apnea by Kaczmarek, Elzbieta et al.
Molecular Biomarkers of Vascular Dysfunction in
Obstructive Sleep Apnea
Elzbieta Kaczmarek1*, Jessie P. Bakker2, Douglas N. Clarke1, Eva Csizmadia1, Olivier Kocher3,
Aristidis Veves4, Francesco Tecilazich4, Christopher P. O’Donnell5, Christiane Ferran1, Atul Malhotra2,6
1Center for Vascular Biology Research, Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, Massachusetts, United States of America, 2Division of Sleep Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts,
United States of America, 3Center for Vascular Biology Research, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
Massachusetts, United States of America, 4Microcirculation Lab and Joslin-Beth Israel Deaconess Foot Center, Department of Surgery, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, Massachusetts, United States of America, 5Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 6Division of Pulmonary and Critical Care Medicine, University of California San Diego, La Jolla,
California, United States of America
Abstract
Untreated and long-lasting obstructive sleep apnea (OSA) may lead to important vascular abnormalities, including
endothelial cell (EC) dysfunction, hypertension, and atherosclerosis. We observed a correlation between microcirculatory
reactivity and endothelium-dependent release of nitric oxide in OSA patients. Therefore, we hypothesized that OSA affects
(micro)vasculature and we aimed to identify vascular gene targets of OSA that could possibly serve as reliable biomarkers of
severity of the disease and possibly of vascular risk. Using quantitative RT-PCR, we evaluated gene expression in skin
biopsies of OSA patients, mouse aortas from animals exposed to 4-week intermittent hypoxia (IH; rapid oscillations in
oxygen desaturation and reoxygenation), and human dermal microvascular (HMVEC) and coronary artery endothelial cells
(HCAEC) cultured under IH. We demonstrate a significant upregulation of endothelial nitric oxide synthase (eNOS), tumor
necrosis factor-alpha-induced protein 3 (TNFAIP3; A20), hypoxia-inducible factor 1 alpha (HIF-1a?? and vascular endothelial
growth factor (VEGF) expression in skin biopsies obtained from OSA patients with severe nocturnal hypoxemia (nadir
saturated oxygen levels [SaO2],75%) compared to mildly hypoxemic OSA patients (SaO2 75%–90%) and a significant
upregulation of vascular cell adhesion molecule 1 (VCAM-1) expression compared to control subjects. Gene expression
profile in aortas of mice exposed to IH demonstrated a significant upregulation of eNOS and VEGF. In an in vitro model of
OSA, IH increased expression of A20 and decreased eNOS and HIF-1a expression in HMVEC, while increased A20, VCAM-1
and HIF-1aexpression in HCAEC, indicating that EC in culture originating from distinct vascular beds respond differently to
IH stress. We conclude that gene expression profiles in skin of OSA patients may correlate with disease severity and, if
validated by further studies, could possibly predict vascular risk in OSA patients.
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Introduction
Symptomatic obstructive sleep apnea (OSA) is a breathing
disorder that affects 6–13% of the adult Western population [1]. In
addition to daytime sleepiness, OSA is implicated in the
pathogenesis of cardiovascular diseases, including hypertension,
coronary artery disease, congestive heart failure, stroke, cardiac
arrhythmias, and sudden cardiac death. The mechanisms by
which OSA affects the cardiovascular system may result from
excursions in intrathoracic pressure, sympathoexcitation, and
intermittent hypoxemia (IH; cycles of oxygen desaturation and
re-oxygenation) [2]. Untreated OSA induces oxidative stress,
inflammation, and endothelial cell (EC) dysfunction [3], which
have been confirmed in animal models of OSA [4]. These
abnormalities are linked to impaired activity of endothelial nitric
oxide synthase (eNOS), an enzyme that generates nitric oxide
(NO), and whose bioavailability is required for normal function of
the endothelium [5,6].
In the last few years, increased systemic levels of several
inflammatory markers, including TNF-a, IL-6, IL-8 and ICAM-1,
have been associated with OSA, suggesting that inflammation
plays an important role in the pathophysiology of OSA, and
possibly its vascular complications [7,8,9,10,11]. However, the role
of HIF-1a, a transcription factor essential for oxygen homeostasis
that is activated in response to hypoxia remains controversial in
OSA studies [11,12,13]. Intermittent hypoxia-induced increase in
HIF-1a protein levels has been suggested as an adaptive response
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to OSA [12,14,15]; however, negative effects of HIF-1a activation,
such as hypertension and ischemic injury, have also been reported
in animal models of OSA [16].
Although OSA is a fairly well investigated disease, the
mechanistic insights into its effects on the vasculature, and
specifically EC dysfunction, remain to be elucidated. Given the
heavy health burden that the cardiovascular risk of OSA
represents, reliable biomarkers that could estimate this risk and
help define preventive and therapeutic measures are clearly
needed [17]. Clinical data suggest variable cardiovascular risk in
OSA populations, and indicate that both protective and delete-
rious pathways may be affected in OSA. Accordingly, defining the
mechanisms underlying differential patient susceptibility to OSA
consequences is desirable. In this study, we analyzed expression
levels of select genes, chosen based on their involvement in the
inflammatory/adaptive response of the vasculature to hypoxia, in
skin biopsies of patients with OSA. Our aim was to identify a
‘‘gene signature’’ panel in the skin of OSA patients that could
serve as a diagnostic and prognostic biomarker of disease severity,
and ultimately to predict possible cardiovascular risk in the future,
after validation in long-term clinical studies. In addition, we aimed
to validate this gene signature in experimental models of OSA,
using mice and in vitro cell cultures exposed to IH. We
hypothesized that the pattern of gene regulation in mouse aorta
and EC exposed to IH is also exhibited in the skin vasculature of
OSA patients.
Materials and Methods
Participants
Non-smoking, adult subjects (median age 40 years, range 20–
65; median body mass index (BMI) 42.5 kg/m2) were included in
this study, with twelve subjects in each group: OSA patients with
severe hypoxemia (apnea-hypopnea index (AHI)$10/h, plus
overnight oxygen saturation nadir ,75%), OSA patients with
mild hypoxemia (AHI$10/h, oxygen saturation nadir $75%),
and healthy controls (AHI,10/h) (Table 1). Subjects with major
cardiac, respiratory, metabolic or sleep disorders other than OSA
were excluded. There were no significant differences in BMI
between OSA groups; however, the control group was somewhat
younger than both OSA groups. All polysomnography (PSG)
variables were within the normal range for the control group, with
increasing AHI for the OSA groups with mild and severe
hypoxemia. The study was approved by the Partners’ Human
Research Committee, and all subjects gave written informed
consent. While some subjects participated in prior research [18],
none of the findings of the present study has been previously
published.
Study design
This was a cross-sectional study that consisted of a screening
visit to ensure eligibility, and standard in-laboratory diagnostic
polysomnography (PSG) conducted between 10 PM and 6 AM,
followed by microcirculatory reactivity testing and a skin biopsy
obtained after PSG completion. Subjects were asked to adhere to a
low-nitrate diet for 72 h prior to admission. Subjects fasted and
refrained from physical exercise from admission until test
completion.
Measurements
Polysomnography. PSGs were conducted and scored by
blinded, registered sleep technicians according to standard criteria
[16]. An apnea was scored if airflow was absent for ten seconds,
and a hypopnea was scored if there was at least a 50% reduction in
airflow for ten seconds or a discernable decrement in airflow for
ten seconds in association with either an oxyhemoglobin
desaturation of at least 3% or an arousal. An apnea-hypopnea
index (AHI) was calculated based on number of apneas and
hypopneas per hour of sleep.
Microcirculatory reactivitymeasurements. Microcirculatory
reactivity measurements were performed between 9:30 and 11:00 AM
for all subjects, following at least 30 min of seated rest in a temperature-
Table 1. Characteristics of the subjects included in the study.
All subjects Controls OSA; mild hypoxemia OSA; severe hypoxemia
n=36 n=12 n=12 n=12
Number of males 12 (34%) 2 (17%) 5 (42%) 5 (42%)
Age (years) 40.0 (26.0) 27.5 (14.8) 51.0 (18.0)# 40.0 (23.5)*
BMI (kg/m2) 42.5 (8.3) 42.7 (8.5) 40.3 (12.2) 42.6 (16.7)
AHI (events/hour) 15.5 (31.7) 3.4 (3.7) 16.0 (8.1)# 52.1 (70.5)*
SaO2 nadir (%) 80.0 (15.8) 87.0 (7.3) 80.0 (6.0) 65.0 (13.8)*
{
Percentage of time asleep with SaO2,90% (%) 8.9 (20.6) 1.9 (8.2) 8.6 (14.3) 44.4 (37.3)*
{
Arousal index (events/hour) 18.4 (22.6) 14.3 (10.9) 23.0 (24.4) 31.3 (29.6)
Glycated hemoglobin (%) 5.6 (0.5) 5.4 (0.3) 5.7 (0.6) 5.7 (0.5)*
Total cholesterol (mg/dL) 182.5 (60.0) 186.0 (67.0) 188.0 (86.3) 179.0 (33.3)
LDL (mg/dL) 106.5 (49.0) 102.0 (51.0) 114.5 (47.0) 111.0 (45.8)
HDL (mg/dL) 46.0 (26.0) 49.0 (26.5) 45.5 (24.8) 43.0 (20.5)
Triglycerides (mg/dL) 115.5 (65.5) 127.0 (48.0) 115.5 (139.5) 99.0 (68.8)
Office systolic BP (mmHg) 116.0 (16.0) 114.0 (14.3) 116.0 (8.0) 127.0 (23.0)
Office diastolic BP (mmHg) 74.0 (12.0) 68.0 (14.5) 76.0 (8.0) 73.5 (13.8)
Gender data are presented as number (%) in each group; all other data are presented as median (interquartile range). AHI = apnea hypopnea index, BMI = body mass
index, BP = blood pressure, HDL = high density lipoprotein, LDL = low density lipoprotein, SaO2 = oxygen saturation.
*p#0.05 OSA severe hypoxemia versus controls; # p#0.05 OSA mild hypoxemia versus controls; { p#0.05 OSA severe hypoxemia versus OSA mild hypoxemia.
doi:10.1371/journal.pone.0070559.t001
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controlled room (24–26uC). LASER Doppler flowmetry (DRT4
Monitor, Moor Instruments Ltd, UK) was used to measure skin blood
flow on the ventral surface of the forearm before and after
iontophoresis of acetylcholine (ACh), and before and after iontopho-
resis of sodium nitroprusside (SNP), using the MIC1 iontophoresis
system (Moor Instruments Ltd, UK), as previously described [19]. The
percentage increase in skin blood flow following ACh and SNP
represents the endothelium-dependent and endothelium-independent
vasodilatory response, respectively. Additional methodological details
including reproducibility of the technique have been described
previously [20].
Skin biopsies. Tissue collection was performed between
11:00 AM and 12:00 noon. Two-mm skin punch biopsies were
obtained from the volar aspect of the forearm under 1% lidocaine
local anesthesia. Specimens were immediately flash-frozen in
liquid nitrogen and stored at 280uC.
Mouse model of OSA
This study was approved by the Institutional Animal Care and
Use Committee at the University of Pittsburgh Medical Center
and complied with the American Physiological Society Guidelines
for Animal Studies. Male C57BL/6J mice (20–25 g body weight,
9–12 weeks old) were purchased from the Jackson Laboratory (Bar
Harbor, ME). Mice were housed in customized cages delivering
IH or intermittent room air (IA; control) stimulus, as described
[21]. This approach allowed mice to be maintained in their
normal environment throughout the protocol. Briefly, a gas
control delivery system regulated the flow of room air, N2, and O2
into the customized cages housing the mice. A series of
programmable solenoids and flow regulators enabled inspired
O2 to be varied from 20.9 to 5.0–6.0% over a 30-s period,
followed by a rapid, 30-s reoxygenation to room air levels, using a
burst of 100% O2. Hypoxic events occurred at a rate of one event
per minute throughout the 12-h light period (8 AM – 8 PM).
During the 12-h dark period (8 PM – 8 AM), mice were
maintained in constant undisturbed room air environment.
Control mice (sham exposure) were exposed to the same gas flow
as IH animals, but only room air was used. Mice were exposed to
28 consecutive days of IH or IA, and then anesthetized and their
aortas removed and snap frozen in liquid nitrogen.
Cell culture and treatment
Human dermal microvascular endothelial cells (HMVEC) were
obtained from Dr. Don Sanger, Beth Israel Deaconess Medical
Center, Boston, MA. Human coronary artery endothelial cells
(HCAEC) were purchased from Lonza (Basel, Switzerland). Cells
were cultured in EGM-2 MV BulletKit medium at 37uC in a 5%
CO2 humidified air incubator.
Confluent cells at passage 5 to 8 were used in all experiments.
One ml of growth medium was added to confluent EC cultures (in
3-cm culture plates) 1 h before IH treatment. Cells (in plates without
lids to obtain better exposure to gases) were placed in the IH
chamber connected to the oxygen controller (Coy Laboratory
Products, Inc., Grass Lake, MI, USA), and oxygen cycling was
induced through controller-regulated purging of oxygen and
nitrogen. Gases were delivered to the IH chamber via water
bubblers placed in the tissue culture incubator to maintain adequate
temperature (37uC) and humidification. Continuously monitored
real-time O2 levels served as input to the controller feedback loop.
Cells were exposed to IH for 1 and 2 h, with 9-min cycles comprised
of 1.5 min ramp from 20% to 1% oxygen, 3 min 1% oxygen,
1.5 min ramp from 1 to 20% oxygen, and 3 min 20% oxygen.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total mRNA was isolated from pulverized skin biopsies or
mouse aortas, using Trizol reagent (Sigma), according to the
manufacturer’s protocol. Total RNA from HMVEC and HCAEC
was isolated using RNeasy mini kit from Qiagen (Valencia, CA,
USA). cDNA was synthesized using iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA, USA) immediately after RNA isolation
(to avoid storage-related degradation of RNA samples). Equal
amounts of cDNA, an equivalent of 2.5 ng (skin biopsies and
mouse aortas) or 5 ng (HCAEC and HMVEC) of RNA, were used
in each reaction carried out in iTaq Fast SYBR Green Supermix
with ROX (Bio-Rad, Hercules, CA, USA) using ABI 7500 Fast
Real-time PCR System (Applied Biosystems, Inc., Foster City, CA,
USA).
mRNA levels of eNOS, A20, VCAM-1, HIF-1a, and VEGF
were evaluated using gene-specific primers (Table 2). The
housekeeping genes, 28S or b-actin were used to normalize gene
expression levels. The gene expression is presented as relative
mRNA expression versus a control group.
Table 2. Sequences of primers used in qRT-PCR experiments.
GENE ACESSION FORWARD PRIMER REVERSE PRIMER
H eNOS NM_000603 GTTTGTCTGCGGCGATGTT GCGTGAGCCCGAAAATGTC
H/M A20 NM_009397 CCTCTTCTTCGCCTGCTTTGTCC CCCCGTCACCAAGCCGTTGTACC
H VCAM-1 NM_001078 AAGATGGTCGTGATCCTTGG GGTGCTGCAAGTCAATGAGA
H HIF-1a NM_001530 TGCACAGGCCACATTCACGTA GTTCACAAATCAGCACCAAGCA
H VEGF NM_001171623 GAGCTTCCTACAGCACAACA GGATTTCTTGCGCTTTCGTT
H b-actin NM_001101 GGCACCACACCTTCTACAA AGCCTGGATAGCAACGTAC
H 28S NM_014018 CAGTTCTCTTGGGAATCCAG TTCAGCAAAGGAGTCAATCCAC
M eNOS NM_008713 GTTTGTCTGCGGCGATGTT GCGTGAGCCCGAAAATGTC
M VCAM-1 NM_011693 CTAATTCATGGTAGAATGGCTA TGAAGTCGCATTTAAATCAGGT
M HIF-1a NM_010431 AAACCAGCAGTTACTCATGCAA CATGATCCAGGCTTAACAATTCCA
M VEGF NM_001025257 CATCTTCAAGCCGTCCTGTGT CTCCAGGGCTTCATCGTTACA
M 28S NR_003279 ATACCGGCACGAGACCGATAGTCA GCGGACCCCACCCGTTTACCTC
H – human, M – mouse.
doi:10.1371/journal.pone.0070559.t002
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Statistical analysis
Variables exhibiting non-Gaussian distribution (human skin and
mouse aortas) were transformed using log10 to satisfy normality
(D’Agostino-Pearson normality test or Kolmogorov-Smirnov
normality test, when n,10) and equality of variance (Levene’s
test). Two-group data were compared using t-test. Three-group
parametric data were compared using one-way ANOVA followed
by Tukey’s pairwise comparisons. Three-group non-parametric
results were compared globally using Kruskal-Wallis tests, followed
by Dunn’s pairwise comparisons. Results were presented as
median or mean +/2 SDEV, and were considered statistically
significant when p,0.05 (2-sided).
Results
Endothelium-dependent and -independent
microvascular reactivity
Our results indicate that endothelium-dependent microvascular
reactivity in response to ACh was significantly decreased in
severely hypoxemic OSA patients compared to controls (Fig. 1A).
In contrast, endothelium-independent microvascular reactivity
following administration of SNP was not different across groups
(Fig. 1B).
Expression levels of select genes in skin biopsies of OSA
patients
Our results demonstrating decreased microvascular reactivity in
severely hypoxemic OSA patients prompted us to investigate
whether OSA affects the expression level of genes involved in EC
homeostasis, as well as in adaptive and inflammatory responses of
the vasculature. These included EC specific NOS (eNOS)
[22,23,24], early response anti-inflammatory gene, A20 [25,26],
pro-inflammatory adhesion molecule VCAM-1 [27,28], and
hypoxia-responsive genes, HIF-1a and VEGF [29,30].
As shown in Figure 2, expression of these genes in severely
hypoxemic OSA patients was significantly increased compared
to control subjects (VCAM-1) or to mildly hypoxemic OSA
subjects (the other genes). Levels of eNOS were decreased in
mildly hypoxemic OSA patients as compared to controls. With
the exception of VCAM-1, differences in gene expression were
most evident between severely and mildly hypoxemic OSA
patients.
Expression of select genes in aortas isolated from mice
exposed to chronic IH
We investigated whether the gene expression signature we
identified in the skin vasculature of OSA patients could be
validated in a mouse model of OSA. We measured relative
expression of the same select genes in aortas, as this vascular bed is
targeted for development of accelerated atherosclerosis in OSA
patients [31]. Expression levels of eNOS and VEGF mRNA were
significantly upregulated in mice exposed to IH as compared to IA
(Fig. 3). A similar trend, albeit not significant, was observed for
A20, VCAM-1, and HIF-1a.
Expression of select genes in HMVEC and HCAEC
exposed to IH
An in vitro model of OSA is desirable to study the mechanisms
causing vascular dysfunction of OSA/IH. We chose HMVEC in
order to investigate a similar vascular bed as in our human skin
biopsies, and HCAEC, as the cells preferentially used to study
atherosclerosis and endothelial (dys)function.
Expression levels of eNOS and HIF-1a were significantly
decreased in HMVEC after 2 h of IH (Fig. 4). We noted a similar
trend (though not significant) for VEGF. In contrast, A20 levels
were increased after 1 and 2 h of IH in these cells.
In HCAEC 2-h exposure to IH significantly increased
expression of A20, VCAM-1, and hypoxia-responsive gene HIF-
1a compared to controls (Fig. 5).
Discussion
Identifying a ‘‘molecular signature’’ that could define and/or
predict cardiovascular risk of OSA could be highly beneficial for
diagnostic and prognostic purposes, to evaluate response to
therapies, and to elucidate mechanisms involved in OSA-mediated
vascular dysfunction [17]. In this study, using a minimally invasive
skin biopsy method, we demonstrate, for the first time, that
expression levels of several genes relevant to EC function are
modulated in OSA patients in a way that correlates with disease
severity, and possibly vascular risk.
The gene panel that we investigated included eNOS, whose
function is crucial for EC homeostasis [22,32], the NF-kB
inhibitory gene, A20 [25,33], the pro-inflammatory adhesion
molecule VCAM-1 [27,28], the hypoxia-responsive genes, HIF-1a
and VEGF [29,30]. Due to the experimental constraints (small
Figure 1. Endothelium-dependent microvascular reactivity is
decreased in severely hypoxemic OSA patients. Changes in skin
blood flow were measured at the forearm by scanning LASER Doppler
following administration of acetylcholine (ACh) that stimulates the
endothelium-dependent release of nitric oxide (A) or SNP that releases
nitric oxide in an endothelium-independent manner (B). Data are
presented as box-plots with medians, quartiles and minimum and
maximum values; 12 subjects per group. C – control group; $75% –
OSA group with mild hypoxemia; ,75% – OSA group with severe
hypoxemia.
doi:10.1371/journal.pone.0070559.g001
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sample size) our experiments were designed to study the changes at
the mRNA level only, which may not correspond directly to the
protein expression.
OSA patients have impaired endothelium-dependent vascular
relaxation, as a result of reduced NO bioavailability caused by
decreased eNOS expression and/or activity [3,24,33,34,35,10].
Our data demonstrate that in mildly hypoxemic OSA patients,
despite decreased eNOS mRNA, microvascular reactivity to
acetylcholine treatment was almost not affected compared to the
control group. We postulate that these patients likely produced
Figure 3. Expression of select genes in mouse aortas is affected by IH. Mice were exposed to intermittent hypoxia (IH) or intermittent air (IA)
for 4 weeks. RNA was isolated from mouse aortas followed by cDNA generation and qPCR analysis. The gene expression is presented as relative
mRNA expression versus a control (IA) group. Results for each sample were normalized versus 28S. Data are presented as mean +/2 SDEV. n = 7–12. *
p,0.05.
doi:10.1371/journal.pone.0070559.g003
Figure 2. Expression of select genes in skin of OSA patients is differently regulated in severely hypoxemic (,75% blood oxygen
saturation) and mildly hypoxemic ($75% blood oxygen saturation) OSA groups. Gene expression in skin biopsies obtained from OSA
patients and control subjects was analyzed by qRT-PCR using specific primers, and is presented as relative mRNA expression versus a control group.
Results for each sample were normalized versus 28S. n = 10–12. Data are presented as mean +/2 SDEV. * p,0.05; ** p,0.005. There is a global
statistical significance for all genes in three groups of studied subjects. $75% – OSA group with mild hypoxemia; ,75% – OSA group with severe
hypoxemia.
doi:10.1371/journal.pone.0070559.g002
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sufficient NO to maintain proper vasoreactivity. The molecular
mechanism behind reduced eNOS mRNA levels in response to
mild hypoxemia still needs to be explored.
Unexpectedly, eNOS mRNA levels in severely hypoxemic OSA
patients were comparable to those in controls. However, despite
adequate eNOS mRNA levels, these patients showed significantly
Figure 5. Expression of select genes in HCAEC exposed to IH. RNA was isolated from HCAEC exposed to IH, followed by cDNA generation and
qRT-PCR analysis. The gene expression is presented as relative mRNA expression versus a control group. Results were obtained from at least 3
experiments and each sample was normalized versus b-actin. Data are presented as mean +/2 SDEV. * p,0.05.
doi:10.1371/journal.pone.0070559.g005
Figure 4. Expression of select genes in HMVEC exposed to IH. RNA was isolated from HMVEC exposed to IH, followed by cDNA generation
and qRT-PCR analysis. The gene expression is presented as relative mRNA expression versus a control group. Results were obtained from at least 3
experiments and each sample was normalized versus 28S. Data are presented as mean +/2 SDEV. * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0070559.g004
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impaired microvascular reactivity, which indicates reduced eNOS
activity and NO bioavailability [10]. We believe that decreased
eNOS activity may result from its post-translational modification
induced by OSA-triggered inflammation [8,9,10] that is validated
here by significantly higher VCAM-1 expression in the severely
hypoxemic group compared to control subjects. Future studies will
verify this hypothesis, though eNOS function impairment by post-
translational modifications, independently from its expression
levels, was already documented in response to hypoxia and in
diabetic patients [35,36,37,38,39,40]. From a clinical standpoint,
our data highlight the complexity of mechanisms regulating eNOS
expression and activity in the context of severity of intermittent
hypoxemia.
Our in vivo data demonstrate upregulation of eNOS mRNA in
aortas isolated from mice exposed to chronic, 4-week IH,
compared to control mice. It has been previously established that
in in vivo model of OSA, response to IH during mice sleep time
resulted in severe hypoxemia [41]. Accordingly, we are exploring
whether this OSA mouse model resembles what we observed in
severely hypoxemic OSA patients, i.e., that increased eNOS
mRNA levels associate with severely decreased eNOS activity,
resulting in vascular dysfunction; especially that these mice also
demonstrate vascular inflammation [42,43,44].
In an in vitro model of IH in HMVEC eNOS mRNA levels were
decreased, suggesting that even short-term exposure to IH causes
changes similar to those described earlier in OSA patients and
OSA in vitro model [6,45,46]. However, eNOS mRNA levels did
not change in HCAEC following exposure to IH, indicating that
EC from distinct vascular beds respond differently to the same
hypoxic insult.
In addition to its impact on eNOS, IH, a critical component of
OSA, promotes oxidative stress within the vasculature, causing
vascular and systemic inflammation that culminates in vascular
remodeling and atherosclerosis. Several studies reported increased
levels of proinflammatory molecules in OSA patients
[7,47,48,49,50,51]. We confirmed that the systemic inflammatory
response associated with OSA was also observed in severely
hypoxemic patients’ skin biopsies, as evaluated by increased
mRNA levels of VCAM-1. Similarly, we noted some increase in
VCAM-1 mRNA levels in aortas of mice exposed to IH compared
to mice placed under IA, and in HCAEC exposed to IH compared
to a normoxic control. Beyond supporting existing data [52,53],
these results validate our mouse and cell culture models of OSA, as
they demonstrate the expected inflammatory response to hypoxic
insult.
Moreover, we analyzed expression levels of the NF-kB-
dependent and NF-kB inhibitory protein A20 [25,33,54,55]. We
have previously shown that A20 exerts protective, anti-inflamma-
tory and anti-apoptotic functions in EC [33,55,56]. Our data show
that A20 mRNA was significantly increased in skin biopsies of
severely hypoxemic compared to mildly hypoxemic OSA patients,
which indicates that the inflammatory insult associated with mild
hypoxemia is not sufficient to upregulate A20 transcription. A20
mRNA levels were also increased in our in vitro models of OSA.
Elevation of A20 in response to IH reveals the presence of an
inflammatory milieu associated with chronic OSA, and is in
agreement with observed upregulation of other NF-kB-dependent
genes, such as VCAM-1. Alternatively, upregulation of A20 could
result from hypoxia-induced increase in A20 transcription through
activation of a hypoxia-response element (A/(G)CGTG) recently
identified in the A20 promoter in glioblastoma cell-lines [57].
We also analyzed the expression of HIF-1a, a transcriptional
regulator of oxygen homeostasis, and its downstream target VEGF
[58,59,60], in skin biopsies of OSA patients, and in mouse aortas
and EC cultures exposed to IH. Both HIF-1a and VEGF mRNA
levels were higher in skin of severely hypoxemic OSA patients
compared to mildly hypoxemic group. VEGF expression was also
upregulated in aortas of mice exposed to IH compared to their
respective controls. These findings indicate that in those tissues
only a significant hypoxic insult exerts a response to hypoxia. The
different effects of IH on HIF-1a mRNA levels in HMVEC and
HCAEC further highlight heterogeneity among EC originating
from different vascular beds, mainly in terms of their susceptibility
to IH.
While many studies support the hypothesis that IH upregulates
HIF-1a, some reports show no impact of OSA on HIF-1a
expression [61]. Although we have not confirmed that HIF-1a
mRNA levels translate into protein, we have indirect evidence that
HIF-1a protein levels likely parallel mRNA levels [62]. VEGF
promotes angiogenesis, a key physiologic adaptive response of
tissues to hypoxia and probably IH. VEGF has also been
implicated through its pro-inflammatory effects in the pathogen-
esis of atherosclerosis [63,64]. Further studies are planned to
evaluate whether increased VEGF in severely hypoxemic patients
is truly adaptive and protective of cardiovascular events or,
contrary, is a marker of increased inflammation, and hence of
increased cardiovascular risk. Some studies do suggest that OSA
patients free of known cardiovascular risk factors have increased
circulating levels of VEGF [65,66,67,68].
Likewise, we plan to evaluate whether decreased VEGF mRNA
levels in patients with mild hypoxemia are indicative of increased
vascular risk, or mark a lower inflammatory insult and hence lesser
vascular risk. More mechanistic studies addressing these questions
could now be envisioned in our mouse and cell culture models of
IH, although we do recognize that the cell culture system is limited
to studying EC responses, whereas gene profiling obtained from
skin biopsies and whole aortas reflects the ‘‘transcriptome’’ of
several cell types that can also modulate their expression of HIF-
1a, and VEGF in response to IH.
In summary, our data demonstrate that gene expression profile
in skin biopsies of OSA patients varied according to severity of
hypoxemia. Even though more investigations are required to
determine the contribution of these differences in mRNA levels of
eNOS, VEGF, A20 and HIF-1a to the pathophysiology of OSA-
induced vascular dysfunction, these genes represent potential
markers distinguishing mildly from severely hypoxemic OSA
patients. Since the genes we investigated are relevant to EC
functions, we anticipate that their molecular signature could be
useful in evaluating the cardiovascular risk in OSA patients.
Further long-term studies of a larger cohort of patients are planned
to validate this assumption.
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